Imagine A World
Where one company makes a difference, saving lives, through the earliest detection of deadly diseases and improving traffic safety.
The Vantage Sensor - improving outcomes and reducing costs
Vantage mHealthcare is developing a sensor that will screen for the Volatile Organic Compound signatures in a person’s breath. Our device and application (working with any smart phone, laptop or tablet) will be able to identify the presence of lung cancer from a single exhalation. Results will be able to be viewed by patient and doctor in-the-moment and when treatment options are discussed. The Vantage Sensor was developed to address one of the longest standing unmet medical needs today which involves early stage lung cancer detection and to do so in an affordable, non-invasive, safe and convenient way.
Similarly, the device will be used by law enforcement to detect the presence of marijuana on a driver’s breath. As more and more states legislate the use of marijuana for medical use the risk of driving while drugged increases as does the death toll. Currently, this represents a significant unmet need as law enforcement struggles with multiple interventions to attempt to assess the condition of drivers that, if not legally intoxicated, appear to be drugged. The Vantage Sensor and its application will provide in-the-moment results with a goal of making our roads safer for all drivers and creating a more effective tool for law enforcement.
Joseph C. Peters
Board of Directors:
Chairman of the Board:
Dr. Steven Steinhubl M.D.
Tony van Bijleveld
Vantage Health in the News
USA TODAY - The Future Of Health Care Is Social And Techie
March 8, 2014
ISSUU - Government Health Care United States Buyers Guide: Winter 2014
Meditek - Could A Smartphone Detect Lung Cancer?
Mobile Health News - Scripps To Test NASA-Developed, Smartphone-Enabled Lung Cancer Sensor
February 11, 2014
Independant Valuations of VNTH
WealthMakers target of $ .50 and a short squeeze valuation of $2.85
WEALTHMAKERS.COM Issues Report on Vantage Health
Wed Feb 26, 7:23AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Vantage Health, Inc. (OTC: VNTH). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $0.095 and the projected short squeeze price target of $2.85 per share.
BUYINS.NET Issues Vantage Health SqueezeTrigger Report
Thu Feb 13, 7:27AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Vantage Health (OTCBB: VNTH) after releasing the latest short sale data through February 11, 2014. The total aggregate number of shares shorted since March 2011 is approximately 23.35 million shares. Approximately 21.83% of daily trading volume is short selling.